Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Regulación y derecho · 7/9/20161 min de lectura
Prospective Grant of Exclusive Patent License: The Development of an Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment of Human Cancers
Traducción automática local · Idioma original de la fuente
Resumen
This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following Patents and Patent Applications and all continuing U.S. and foreign patents/ patent applications to Sangamo BioSciences, Inc. located in Richmond, California, USA:
Idioma original de la fuente: Federal Register — All DocumentsAbrir el comunicado original →